Logo
About usInnovation CMChallengesEuropaEntrepreneurshipR&D&I SearchAgentsEventsReports
en
NEW ANTHRAQUINONIC DERIVATIVES HAVING AN ANTITUMOR ACTIVITY, AND APPLICATIONS THEREOFCM Patents

PCT No. PCT/ES95/00024 Sec. 371 Date Mar. 27, 1996 Sec. 102(e) Date Mar. 27, 1996 PCT Filed Feb. 24, 1995 PCT Pub. No. WO95/23145 PCT Pub. Date Aug. 31, 1995Said derivatives have the general formula (I) and are: <IMAGE> (I) (I-A) 4,6,7-trimethyl-5,8,8a,10a-tetrahydro-1H-1-azaanthracen-2,9,10-trione; (I-B) 2-ethoxy-3-methyl-1-azaanthracen-9,10-dione; (I-C) 3-ethyl-1,8-dihydro-1H-1,8-diazaanthracen-2,7,9,10-tetraone; (I-d) 2-acethoxy-3-methyl-1,8-diazaanthracen-2,9,10-trione; (I-e) 6-fluor-4-methyl-1H-1,8-diazaanthracen-2,9,10-trione; (I-f) 6-dimethylamino-4-methyl-1H-1,8-diazaanthracen-2,9,10-trione; (I-g) 4-methyl-5-(2-nitrophenyl)-5,8-dihydro-1H-1,8-diazaanthracen-2,9,10-trione; (I-h) 3,5-dimethyl-1,8-dihydro-1,8-diazaanthracen-2,7,9,10-tetraone; (I-i) 3,6-difluor-1,8-diazaanthracen-9,10-dione; (I-j) 6-methyl-3-phenyl-1H-1,8-diazaanthracen-2,9,10-trione; (I-k) 3-fluor-4-methyl-1-dihydro-1-azaanthracen-9,10-dione; 3-fluor-1-azaanthracen-1,10-dione. Application as antitumor agents.

Datos clave

CategoríaInvención

Índice de la ficha

Updated at
05/11/2026
Numero publicacion
EP.0695752.A1
Fecha publicacion
07/02/1996
Anio publicacion
1996

En detalle

Reivindicaciones

1. new anthraquinonic derivatives having antitumor activity, characterized in that they have the following general formula (I): <img class="EMIRef" id="429140160-ib0010" /> wherein the broken line represents a double bond that may or may not be present and A and B form, together with the center ring, an anthraquinonic system that responds to the following pairs of meanings A and B: <img class="EMIRef" id="429140160-ib0011" /> <img class="EMIRef" id="429140160-ib0012" /> the broken line representing a double bond in all cases except in (a) in which said double bond is not present. 2. New anthraquinonic derivative, according to claim 1, characterized in that it has the following formula (I-a): <img class="EMIRef" id="429140160-ib0013" /> 3. New anthraquinonic derivative, according to claim 1, characterized in that it has the following formula (I-b): <img class="EMIRef" id="429140160-ib0014" /> 4. New anthraquinonic derivative, accoording to claim 1, characterized in that it has the following formula (I-c): <img class="EMIRef" id="429140160-ib0015" /> 5. New anthraquinonic derivative, according to claim 1, characterized in that it has the following formula (I-d): <img class="EMIRef" id="429140160-ib0016" /> 6. New anthraquinonic derivative, according to claim 1, characererized in that it has the following formula (I-e): <img class="EMIRef" id="429140160-ib0017" /> 7. New anthraquinonic derivative, according to claim 1, characterized in that it has the following formula (I-f): <img class="EMIRef" id="429140160-ib0018" /> 8. New anthraquinonic derivative, according to claim 1, characterized in that it has the following formula (I-g): <img class="EMIRef" id="429140160-ib0019" /> 9. New anthraquinonic derivative, according to claim 1, characterized in that it has the following formula (I-h): <img class="EMIRef" id="429140160-ib0020" /> 10. New anthraquinonic derivative, according to claim 1, characterized in that it has the following formula (I-i): <img class="EMIRef" id="429140160-ib0021" /> 11. New anthraquinonic derivative, according to claim 1, characterized in that it has the following formula (I-j): <img class="EMIRef" id="429140160-ib0022" /> 12. New anthraquinonic derivative, according to claim 1, characerterized in that it has the following formula (I-k): <img class="EMIRef" id="429140160-ib0023" /> 13. New anthraquinonic derivative, according to claim 1, characterized in that it has the following formula (I-l): <img class="EMIRef" id="429140160-ib0024" /> 14. Application of the anthraquinonic derivatives of formula (I) defined in claim 1 as antitumor agents. 15. Application of the anthraquinonic derivative of formula (I-a) of claim 2 as an antitumor agent. 16. Application of the anthraquinonic derivative of formula (I-b) of claim 3 as an antitumor agent. 17. Application of the anthraquinonic derivative of formula (I-c) of claim 4 as an antitumor agent. 18. Application of the anthraquinonic derivative of formula (I-d) of claim 5 as an antitumor agent. 19. Application of the anthraquinonic derivative of formula (I-e) of claim 7 as an antitumor agent. 20. Application of the anthraquinonic derivative of formula (I-f) of claim 7 as an antitumor agent. 21. Application of the anthraquinonic derivative of formula (I-g) of claim 8 as an antitumor agent. 22. Application of the anthraquinonic derivative of formula (I-h) of claim 9 as an antitumor agent. 23. Application of the anthraquinonic derivative of formula (I-i) of claim 10 as an antitumor agent. 24. Application of the anthraquinonic derivative of formula (I-j) of claim 11 as an antitumor agent. 25. Application of the anthraquinonic derivative of formula (I-k) of claim 12 as an antitumor agent. 26. Application of the anthraquinonic derivative of formula (I-l) of claim 12 as an antitumor agent. 27. Application of any one of the anthraquinonic derivatives of formulae (I-a) to (I-l) defined in the above claims 2 to 13 for the manufacture of drugs for the treatment of tumors.

Etiquetas

Inventores
Aveda O Lopez, CarmenAveda O Lopez CarmenGarcia Gravalos DoloresGarcia Gravalos, DoloresAvendano Lopez CarmenAvendano Lopez, CarmenAvendao LopezAvendao Lopez CarmenCarmenGarcia GravalosDolores
Solicitantes
Universidad Complutense de Madrid
Clasificacion ipc
A61K 31/ 435 A IA61P 35/ 00 A IC07D 221/ 08 A IC07D 221/ 10 A IC07D 471/ 04 A I
Clasificacion cpc
4C065/AA044C065/AA194C065/BB094C065/CC094C065/DD024C065/EE024C065/HH014C065/HH024C065/HH044C065/JJ024C065/JJ044C065/KK014C065/KK024C065/KK054C065/KK104C065/LL014C065/LL024C065/LL044C065/LL074C065/LL104C065/PP014C065/PP034C086/AA014C086/AA024C086/AA034C086/BC274C086/BC284C086/NA144C086/ZB26A61K31/435A61P35/00C07D221/10C07D471/04&112514/290514/292546/79546/81
Logo

Innovation CM
Challenges
Europa
Entrepreneurship
R&D&I Search
Agents
Events
Reports
About us
Contact
Give us your opinion
Cookies
Legal notice
Privacy

© Copyright Espacio Madrileño de Investigación e Innovación 2026